# Institutional investment in Denali Therapeutics

> Live situation record from CLSTR: https://clstr.news/situations/institutional-investment-in-denali-therapeutics
> Updated: 2026-08-11T09:29:04.000Z. Sources: 2. Developments: 2.

Institutional investors have shown increased interest in Denali Therapeutics Inc. through significant stake acquisitions. Defilade Capital Management L.P. more than doubled its position in the first quarter, holding approximately 1,359,969 shares. Other major entities, including Norges Bank, Goldman Sachs Group, and T. Rowe Price, have also contributed to the firm’s institutional ownership.

## Timeline

### 2026-08-11: Institutional investors adjust holdings in Denali Therapeutics and Delta Air Lines

Recent SEC filings show Sei Investments Co. taking a new position in Denali Therapeutics and Revolve Wealth Partners LLC investing $1.38 million in Delta Air Lines.

2 sources. https://clstr.news/cluster/institutional-investors-adjust-holdings-in-denali-therapeutics-and-delta-air-lines

### 2026-08-02: Institutional investors boost holdings in Denali Therapeutics and ADMA Biologics

Defilade Capital and other funds expanded holdings in Denali Therapeutics, while Dimensional Fund Advisors increased its stake in ADMA Biologics, reflecting growing institutional interest in biotech stocks.

2 sources. https://clstr.news/cluster/delta-air-lines-institutional-share-changes-in-q1-filings

---
Cite as: Institutional investment in Denali Therapeutics. CLSTR, https://clstr.news/situations/institutional-investment-in-denali-therapeutics